Peptide Bio IndexEvidence first. Hype last.
⌕

CJC-1295 Benefits, Uses, and Protocols: What Published Research Reports

Written by

in

Benefits & Uses
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited9 min readUpdated Aug 26, 2026
Jump to a section
  1. What is CJC-1295?
  2. Why researchers study it
  3. Benefits discussed in literature
  4. Uses discussed in research
  5. Mechanisms discussed in published studies
  6. Reported study designs and protocol examples
  7. Protocol table from cited sources
  8. Limitations and research gaps
  9. Documentation checklist
  10. Related research supplies
  11. More CJC-1295 research
  12. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

This article summarizes findings from the provided reviewed sources about CJC-1295, a long-acting growth hormone–releasing hormone (GHRH) analog, focusing on what published research reports regarding its properties, studied uses, reported effects, mechanisms, and example study designs.

What is CJC-1295?

CJC-1295 is described in the literature as a synthetic, long-acting analog of growth hormone–releasing hormone (GHRH) developed to prolong stimulation of pituitary growth hormone (GH) secretion compared with native GHRH. [S1] [S8]

Why researchers study it

Researchers have investigated CJC-1295 because native GHRH has a short duration of action and a long‑acting GHRH analog could provide sustained GH/IGF‑I activation for therapeutic or investigational uses; reviews of peptide therapeutics also list CJC-1295 among GH‑axis agonists of interest for tissue repair and recovery research. [S1] [S2] [S3]

Benefits discussed in literature

In a randomized, placebo-controlled human trial, subcutaneous CJC-1295 produced sustained, dose‑dependent increases in plasma GH (reported as 2- to 10‑fold increases lasting six days or more after a single injection) and increases in IGF‑I (reported as 1.5- to 3‑fold for 9–11 days), with evidence of cumulative IGF‑I elevation after multiple doses. [S1]

Proteomic analysis of sera from human subjects after CJC-1295 injection identified several serum protein changes that correlated with GH/IGF‑I activation and suggested potential biomarkers of GH/IGF‑I action. [S6]

Preclinical literature and review articles discuss CJC-1295 (often alongside other GH secretagogues) as an activator of IGF‑I signaling with potential relevance to satellite cell repair and muscle outcomes in animal models, though clinical orthopaedic evidence is limited. [S2] [S3]

Consumer- and forum-reported motivations for using CJC-1295 (from netnography studies) include perceived benefits such as weight loss, muscle enhancement, improved skin or sleep, and injury healing, but these are user reports rather than controlled evidence. [S7]

Uses discussed in research

Clinical research has explored CJC-1295 as a potential therapeutic agent to stimulate GH and IGF‑I in healthy adults and to evaluate its pharmacokinetics and safety profile in controlled trials. [S1]

Reviews of therapeutic peptides place CJC-1295 among GH‑axis agents of interest for regenerative medicine, orthopaedic injury recovery, and sports medicine contexts, but they also emphasize a lack of robust clinical trials supporting orthopaedic or performance applications. [S2] [S3] [S4]

Analytical and anti‑doping literature includes CJC-1295 among GHRH synthetic analogs investigated for in vitro metabolism and urine detection methods, reflecting both research‑use detection efforts and its inclusion in prohibited substance lists. [S8]

Mechanisms discussed in published studies

CJC-1295 acts as a GHRH analog to activate the GH/IGF‑I axis, producing measurable increases in circulating GH and downstream IGF‑I concentrations in humans. [S1] [S6]

Proteomic profiling after CJC-1295 administration identified changes in multiple serum proteins (including albumin fragments, immunoglobulin fragments, apolipoprotein A1 isoform, and transthyretin isoform) that correlated with GH/IGF‑I activation, suggesting possible downstream biochemical signatures of GH axis stimulation. [S6]

Reviews place CJC-1295 among peptides that ultimately engage IGF‑1 signaling pathways implicated in tissue regeneration, satellite cell repair, and anabolic processes, although mechanistic detail in humans remains limited in the reviewed literature. [S2] [S3]

Reported study designs and protocol examples

Human randomized, placebo‑controlled, double‑blind ascending‑dose trials evaluated subcutaneous CJC-1295 in healthy adults with study durations of 28 and 49 days; the trials reported single injection administration in the first study and two‑ or three‑weekly or biweekly dosing in the second study, with reported tolerability at doses cited as 30 or 60 microg/kg and an estimated peptide half‑life of 5.8–8.1 days. [S1]

A proteomic research study analyzed sera from 11 healthy young adult men sampled before and one week after CJC-1295 injection to identify serum protein changes associated with GH/IGF‑I activation. [S6]

An analytical validation study used in vitro fortified urine to characterize metabolism and detection of several GHRH synthetic analogs (including CJC-1295), identifying major in vitro metabolites and developing an LC–MS/MS method with limits of detection generally at or below ~1 ng/mL for target peptides. [S8]

Preclinical reports referenced in reviews include murine experiments where CJC-1295 combined with ipamorelin was associated with improved maximum tetanic tension in models of glucocorticoid‑induced muscle loss; explicit dosing, route, frequency, and duration details were not reported in the reviewed excerpt. [S3]

Protocol table from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S1] Randomized controlled trial Healthy human adults (ages 21–61 yr) 30 or 60 microg/kg (other ascending doses not specified in the reviewed excerpt) Subcutaneous Single injection (first study) and two- or three‑weekly or biweekly doses (second study) Study durations of 28 and 49 days; peptide half-life estimated 5.8–8.1 days Dose-dependent increases in GH (2–10x for ≥6 days) and IGF‑I (1.5–3x for 9–11 days); cumulative IGF‑I effects after multiple doses; no serious adverse reactions reported in reviewed excerpt.
[S6] Proteomic research study 11 healthy young adult men not reported in the reviewed source not reported in the reviewed source Samples obtained before and one week after CJC-1295 injection One week between baseline and post‑treatment sampling Two‑dimensional gel electrophoresis and mass spectrometry identified serum protein changes correlated with GH/IGF‑I levels; specific dosing details not provided in reviewed excerpt.
[S8] In vitro analytical validation study Fortified urine samples (in vitro) Limits of detection generally 1 ng/mL or less for target peptides Urine (fortified samples, in vitro) not reported in the reviewed source not reported in the reviewed source Nineteen major in vitro metabolites of GHRH analogs (including CJC-1295) were identified and synthesized to develop a sensitive LC–MS/MS detection method.
[S3] Preclinical (animal) study reported in review Murine models with glucocorticoid‑induced muscle loss not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Review cites that CJC-1295 combined with ipamorelin improved maximum tetanic tension in these murine models; details limited to the review excerpt.

Limitations and research gaps

  • Human randomized trial data are limited to the published early clinical studies summarized here; broader clinical efficacy and long‑term safety data are scarce in the reviewed sources.
  • Many potential uses discussed in reviews are extrapolated from preclinical studies, mechanistic reasoning, or user reports rather than confirmed clinical outcomes.
  • Consumer forum data reflect self‑reports and motivations rather than controlled evidence of benefit or safety.
  • CJC-1295 and related GHRH analogs appear in anti‑doping research and prohibited lists; detection and metabolism studies are ongoing but do not equate to clinical approval or established therapeutic indications.

Documentation checklist

  • Confirm regulatory and approval status from authoritative national regulators before considering clinical use.
  • Review the primary randomized controlled trials and proteomic studies for full methodological details.
  • Distinguish between controlled human trial evidence, preclinical findings, and anecdotal/forum reports when interpreting purported benefits.
  • Consult up‑to‑date anti‑doping guidance if working with athletes or sport populations.
  • Temperature‑monitored storage boxes or freezers for peptide sample storage documentation
  • Laboratory inventory labels and sample tracking log sheets
  • Proteomics sample handling documentation and mass spectrometry chain-of-custody forms
  • Laboratory surface disinfectant wipes and approved cleaning agents

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Portable multi-vial case

Moyite 24-Slot Vial Case

A zippered 24-slot case for organizing compatible 1–3 mL vials during documented storage or transport workflows.

View on Amazon (paid link)

Surface and equipment cleaning

Wipex Individually Wrapped 70% IPA Wipes

Individually wrapped isopropyl alcohol wipes for compatible electronics, tools, equipment, and work surfaces. Follow the manufacturer’s instructions.

View on Amazon (paid link)

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.

More CJC-1295 research

Sources and references

  1. [S1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism. 2006. PMID: 16352683. DOI: 10.1210/jc.2005-1536
  2. [S2] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
  3. [S3] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
  4. [S4] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
  5. [S5] Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.. International journal of molecular sciences. 2026. PMID: 42123471. DOI: 10.3390/ijms27093890
  6. [S6] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2009. PMID: 19386527. DOI: 10.1016/j.ghir.2009.03.001
  7. [S7] Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.. Substance use & misuse. 2016. PMID: 26771670. DOI: 10.3109/10826084.2015.1082595
  8. [S8] Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs.. Drug testing and analysis. 2021. PMID: 34665524. DOI: 10.1002/dta.3183

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts